<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Mutationally activated K-Ras can utilize a multitude of downstream effector proteins to promote <z:e sem="disease" ids="C1326912" disease_type="Neoplastic Process" abbrv="">oncogenesis</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>While the Raf and phosphoinositol 3-kinase effector pathways are the best-studied and validated, recent studies have established the critical importance of Ral <z:chebi fb="1" ids="16235">guanine</z:chebi> nucleotide exchange factor (RalGEF) activation of the RalA and RalB small GTPases in <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> biology </plain></SENT>
<SENT sid="2" pm="."><plain>Due to recent evidence that the RalGEF-Ral pathway is necessary for the tumorigenic and metastatic potential of KRAS mutant <z:mp ids='MP_0009151'>pancreatic ductal adenocarcinoma</z:mp> (<z:mp ids='MP_0009151'>PDAC</z:mp>) <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells, we investigated whether or not Ral signaling was necessary for KRAS mutant <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cell growth </plain></SENT>
<SENT sid="3" pm="."><plain>As in <z:mp ids='MP_0009151'>PDAC</z:mp>, we found upregulated RalA and RalB activation in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cell lines and <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>Surprisingly we found antagonistic roles for RalA and RalB in the regulation of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cell anchorage-independent growth </plain></SENT>
<SENT sid="5" pm="."><plain>This observation contrasts with <z:mp ids='MP_0009151'>PDAC</z:mp>, where RalA but not RalB is necessary for <z:mp ids='MP_0009151'>PDAC</z:mp> <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cell anchorage-independent growth </plain></SENT>
<SENT sid="6" pm="."><plain>Our results emphasize <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cell type differences in Ral function and hence the need for distinct Ral targeted therapeutic approaches in the treatment of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> vs. <z:mp ids='MP_0009151'>PDAC</z:mp> </plain></SENT>
</text></document>